Paul J. Lytle
2018
In 2018, Paul J. Lytle earned a total compensation of $463.1K as Chief Financial Officer at Peregrine Pharmaceuticals, a 34% decrease compared to previous year.
Compensation breakdown
| Salary | $405,600 |
|---|---|
| Other | $57,525 |
| Total | $463,125 |
Lytle received $405.6K in salary, accounting for 88% of the total pay in 2018.
Lytle also received $57.5K in other compensation.
Rankings
In 2018, Paul J. Lytle's compensation ranked 12,124th out of 14,244 executives tracked by ExecPay. In other words, Lytle earned more than 14.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 12,124 out of 14,244 | 15th |
Division Manufacturing | 4,913 out of 5,765 | 15th |
Major group Chemicals And Allied Products | 1,858 out of 2,128 | 13th |
Industry group Drugs | 1,587 out of 1,817 | 13th |
Industry Pharmaceutical Preparations | 1,217 out of 1,391 | 13th |
Source: SEC filing on August 17, 2018.
Lytle's colleagues
We found four more compensation records of executives who worked with Paul J. Lytle at Peregrine Pharmaceuticals in 2018.
2018
Roger Lias
Peregrine Pharmaceuticals
Chief Executive Officer
2018
Steven King
Peregrine Pharmaceuticals
Chief Executive Officer
2018
Joseph Shan
Peregrine Pharmaceuticals
Former Vice President, Clinical & Regulatory Affairs
2018
Mark Ziebell
Peregrine Pharmaceuticals